This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Non-Hodgkin lymphoma
  • /
  • The evolving role of lenalidomide in non-Hodgkin l...

The evolving role of lenalidomide in non-Hodgkin lymphoma.

Read time: 1 mins
Published:1st Jul 2016
Author: Galanina N, Petrich A, Nabhan C.
Ref.:Leuk Lymphoma. 2016 Feb 22:1-10. [Epub ahead of print]

Recent advances in the treatment of patients with non-Hodgkin lymphoma have driven a paradigm shift from standard chemotherapy to an ever-expanding choice of targeted agents and combinations. As an orally bioavailable immunomodulator with antineoplastic, immunologic, and antiproliferative activity in B-cell lymphoma, lenalidomide has emerged as one such option. Lenalidomide demonstrates clinically significant activity with a favorable safety profile as a single agent, as well as in combination therapy. Herein, we review accumulated clinical data on lenalidomide, with particular reference to patients with first-line and relapsed/refractory mantle cell lymphoma, indolent lymphoma, and diffuse large B-cell lymphoma.


Read abstract on library site